Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
作者： Jennifer A. Lo , David E. Fisher , Keith T. Flaherty
DOI: 10.1001/JAMAONCOL.2015.2274
关键词:
摘要: The goal of cancer immunotherapy is to harness the immune system recognize and destroy tumor cells, with potential produce durable responses that may translate into curative outcomes in patients metastatic cancers. Results from multiple randomized clinical trials have established checkpoint inhibitors as most successful class immunotherapies date. These include monoclonal antibodies reinvigorate T cell by blocking cytotoxic lymphocyte antigen-4 (CTLA-4) programmed death-1 (PD-1), two coinhibitory receptors regulate activation.
sci-hub.se 参考文章(7)
Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Matthew Gubens, Sara Alcántara Luna, Kevin Lin, Pietro Quaglino, Klemens Rappersberger, Susana Ortiz-Urda, Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression JAMA Dermatology. ,vol. 151, pp. 1206- 1212 ,(2015) , 10.1001/JAMADERMATOL.2015.1916
Giao Q. Phan, Peter Attia, Seth M. Steinberg, Donald E. White, Steven A. Rosenberg, Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology. ,vol. 19, pp. 3477- 3482 ,(2001) , 10.1200/JCO.2001.19.15.3477
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M. Vaubel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael J. Yellin, Geoffrey M. Nichol, Axel Hoos, Walter J. Urba, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine. ,vol. 363, pp. 711- 723 ,(2010) , 10.1056/NEJMOA1003466
Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss-Schaap, Alain Algazi, Christine Mateus, Peter Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot W. Ebbinghaus, Xiaoyun Nicole Li, S. Peter Kang, Antoni Ribas, Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma The New England Journal of Medicine. ,vol. 369, pp. 134- 144 ,(2013) , 10.1056/NEJMOA1305133
Hansje-Eva Teulings, Jacqueline Limpens, Sophia N. Jansen, Aeilko H. Zwinderman, Johannes B. Reitsma, Phyllis I. Spuls, Rosalie M. Luiten, Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis Journal of Clinical Oncology. ,vol. 33, pp. 773- 781 ,(2015) , 10.1200/JCO.2014.57.4756
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott J. Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D. Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. ,vol. 366, pp. 2443- 2454 ,(2012) , 10.1056/NEJMOA1200690
Michael B. Atkins, James W. Mier, David R. Parkinson, Jody A. Gould, Eugene M. Berkman, Michael M. Kaplan, Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. The New England Journal of Medicine. ,vol. 318, pp. 1557- 1563 ,(1988) , 10.1056/NEJM198806163182401